SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 102 400 KRW -1.54%
Market Cap: 8T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SK Biopharmaceuticals Co Ltd
Note Receivable Peer Comparison

Comparables:
000100
008930
128940
S
000250
C
068760

Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Note Receivable
â‚©84.8m
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Note Receivable
â‚©570.7m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Note Receivable
â‚©19.5B
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Note Receivable
â‚©6.6B
CAGR 3-Years
N/A
CAGR 5-Years
46%
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Note Receivable
â‚©130.7m
CAGR 3-Years
-76%
CAGR 5-Years
N/A
CAGR 10-Years
-27%

See Also

What is SK Biopharmaceuticals Co Ltd's Note Receivable?
Note Receivable
84.8m KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Note Receivable amounts to 84.8m KRW.

What is SK Biopharmaceuticals Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
16%

Over the last year, the Note Receivable growth was 7%.

Back to Top